Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 6INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Glioblastoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × ADI PEG20 × 1 year × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

NCT05001828 2026-01-21

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Polaris Group

Phase 1 Active not recruiting
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05317819 2025-12-18

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Polaris Group

Phase 3 Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04587830 2025-08-26

GBM

Polaris Group

Phase 2 Active not recruiting
100 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡